Ellen O'Connor Vos Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Ellen O'Connor Vos.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Ellen O'Connor Vos. Ellen O'Connor Vos is Director in NTELOS HOLDINGS CORP. ($NTLS) and Director in OptimizeRx Corp ($OPRX).
Latest Insider Trading Transactions of Ellen O'Connor Vos
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Apr 02 2021 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 539 | 0 | 32,483 | 31.9 K to 32.5 K (+1.69 %) |
Apr 01 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 8.75 | 1,000 | 8,750 | 28,022 | 27 K to 28 K (+3.70 %) |
Mar 31 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,784 | 0 | 27,022 | 24.2 K to 27 K (+11.49 %) |
Jan 07 2020 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 24,238 | 22.2 K to 24.2 K (+9.41 %) |
Nov 14 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 9.62 | 600 | 5,772 | 22,154 | 21.6 K to 22.2 K (+2.78 %) |
Oct 02 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 21,554 | 19.5 K to 21.6 K (+10.70 %) |
Mar 29 2019 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,084 | 0 | 17,386 | 15.3 K to 17.4 K (+13.62 %) |
Oct 10 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.00 | 2,084 | 0 | 15,302 | 13.2 K to 15.3 K (+15.77 %) |
Jul 03 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.00 | 2,084 | 0 | 13,218 | 11.1 K to 13.2 K (+18.72 %) |
Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.72 | 250 | 2,680 | 11,134 | 10.9 K to 11.1 K (+2.30 %) |
Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.47 | 1,100 | 11,517 | 10,884 | 9.8 K to 10.9 K (+11.24 %) |
Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.29 | 50 | 515 | 9,784 | 9.7 K to 9.8 K (+0.51 %) |
Jun 27 2018 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 10.35 | 400 | 4,140 | 9,734 | 9.3 K to 9.7 K (+4.29 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 28,000 | 27 K to 28 K (+3.70 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.74 | 2,000 | 1,480 | 27,000 | 25 K to 27 K (+8.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 25,000 | 24 K to 25 K (+4.17 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 24,000 | 23 K to 24 K (+4.35 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 23,000 | 21 K to 23 K (+9.52 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.80 | 1,000 | 800 | 21,000 | 20 K to 21 K (+5.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 20,000 | 19 K to 20 K (+5.26 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 19,000 | 18 K to 19 K (+5.56 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.82 | 2,000 | 1,640 | 18,000 | 16 K to 18 K (+12.50 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 16,000 | 15 K to 16 K (+6.67 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 2,000 | 1,620 | 15,000 | 13 K to 15 K (+15.38 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.81 | 1,000 | 810 | 13,000 | 12 K to 13 K (+8.33 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.85 | 1,000 | 850 | 12,000 | 11 K to 12 K (+9.09 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 1,000 | 700 | 11,000 | 10 K to 11 K (+10.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.71 | 1,000 | 710 | 10,000 | 9 K to 10 K (+11.11 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 1,000 | 750 | 9,000 | 8 K to 9 K (+12.50 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 8,000 | 7 K to 8 K (+14.29 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.70 | 2,000 | 1,400 | 7,000 | 5 K to 7 K (+40.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.75 | 2,000 | 1,500 | 5,000 | 3 K to 5 K (+66.67 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.73 | 1,000 | 730 | 3,000 | 2 K to 3 K (+50.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.76 | 1,000 | 760 | 2,000 | 1,000 to 2 K (+100.00 %) |
May 31 2017 | OPRX | OptimizeRx Corp | Vos Ellen O'Connor | Director | Buy | P | 0.77 | 1,000 | 770 | 1,000 | 0 to 1,000 |
May 06 2016 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | M | 0.00 | 2,847 | 0 | 0 | |
May 06 2016 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Sell | D | 9.25 | 28,604 | 264,587 | 0 | 28.6 K to 0 (-100.00 %) |
May 06 2016 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Buy | M | 0.00 | 2,847 | 0 | 28,604 | 25.8 K to 28.6 K (+11.05 %) |
Jan 06 2016 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | A | 0.00 | 8,206 | 0 | 8,206 | |
Jan 06 2015 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 18,293 | 0 | 25,757 | 7.5 K to 25.8 K (+245.08 %) |
Jan 06 2014 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | A | 19.67 | 5,434 | 106,887 | 5,434 | |
Jan 06 2014 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,019 | 0 | 7,464 | 5.4 K to 7.5 K (+37.08 %) |
Jan 04 2013 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | A | 11.83 | 8,600 | 101,738 | 8,600 | |
Jan 04 2013 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,891 | 0 | 5,446 | 2.6 K to 5.4 K (+113.15 %) |
Jan 05 2012 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | A | 20.93 | 6,200 | 129,766 | 6,200 | |
Jan 05 2012 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 2,062 | 0 | 2,555 | 493 to 2.6 K (+418.26 %) |
Nov 15 2011 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Option Exercise | A | 21.15 | 1,116 | 23,603 | 1,116 | |
Nov 14 2011 | NTLS | NTELOS HOLDINGS CO ... | Vos Ellen O'Connor | Director | Grant | A | 0.00 | 493 | 0 | 493 | 0 to 493 |
Page: 1